Stefan Blaas

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 490 citations · Full text

Antifibrotic Therapy, Advanced Lung Disease, Idiopathic Pulmonary Fibrosis +6

High proportion of large genomic deletions and a genotype–phenotype update in 80 unrelated families with juvenile polyposis syndrome

Stefan Aretz, Dietlinde Stienen, Siegfried Uhlhaas et al. · Journal of Medical Genetics · 2007 · 244 citations · Full text

A Novel Extracorporeal CO2 Removal System

Nausherwan K. Burki, Raj Mani, Felix Herth et al. · CHEST Journal · 2013 · 210 citations · Full text

Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial

Gaëtan Deslée, Karin Klooster, Martin Hetzel et al. · Thorax · 2014 · 135 citations · Full text